At Ajanta scientific excellence is at our heart as we embrace R&D as an integral part of our business strategy.
We have been consistently investing in it for decades, making it the driving force behind our differentiation: to develop patient-centric products that enhance convenience, adherence and outcomes. Our core strength lies in our ability to excel in developing differentiated generic and fixed dose combinations products backed by our dedicated teams in formulations development, process chemistry, and analytical development. This has helped in building a competitive advantage.
Our R&D facility in Mumbai is spread across 100,000 sq. ft. area and has 850+ diligent and committed scientists.
The facility has a range of state-of-the-art equipment for formulation development, working on different dosage forms such as tablets, capsules, powders, oral liquid, topical creams/ointments/lotions, sterile eye drops/suspension, nasal sprays, dry powder inhalers, and injectable
We also have an equally well-equipped Active Pharmaceutical Ingredient (API) lab dedicated to synthesizing high value APIs for some of our key products.
Many of the formulations developed by our R&D are first of its kind and now hold leading positions within their sub-therapeutic segments across various geographies.
The research centre’s focus is on developing new formulations to introduce 1st to market products that enhance patient convenience and compliance.
We continuously adopt and integrate the latest technologies to fuel innovation and accelerate product development.
One of our most notable R&D achievements is Met XL, our flagship anti-hypertensive brand. It was the first generic extended-release formulation of Metoprolol launched in India. The once-a-day dosage has significantly improved patient convenience and compliance, setting a benchmark for innovation in its segment.
A patient who has suffered a heart attack has to generally take more than 10 medicines a day. It naturally makes compliance for patients difficult. Ajanta’s 1st to Market Rosutor Gold is a combination of three molecules: Rosuvastatin, Aspirin, and Clopidogrel. While statin helps in lowering cholesterol levels, the other two work on resolving clots in arteries.
Alcarex (Alcaftadine) is another example of our innovative capabilities. Before Ajanta launched this product, it would take patients of allergic conjunctivitis about 15 minutes to get relief from the available products. With the launch of the US FDA-approved Alcaftadine in India, patients could get relief in just 3 minutes. Moreover, the effect of a dose lasts for 24 hours.
Our team is provided with an environment that nurtures excellence and innovation, which is most essential to develop complex and challenging first-time combination products.
The R&D team is involved in all projects from concept to Phase IV study besides tracking market acceptability and after-launch status.
